Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-09-28
DOI
10.1093/annonc/mdz407
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
- (2019) Sebastian Michels et al. Journal of Thoracic Oncology
- MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
- (2019) Robin Guo et al. Journal of Thoracic Oncology
- Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
- (2019) Mark M. Awad et al. LUNG CANCER
- Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial
- (2019) Lorenza Landi et al. CLINICAL CANCER RESEARCH
- 493OTepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data
- (2018) H Sakai et al. ANNALS OF ONCOLOGY
- LBA52Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)
- (2018) J Wolf et al. ANNALS OF ONCOLOGY
- Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
- (2017) Alexis B. Cortot et al. JNCI-Journal of the National Cancer Institute
- Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
- (2017) Alexis B. Cortot et al. JNCI-Journal of the National Cancer Institute
- Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
- (2016) Sinéad A. Noonan et al. Journal of Thoracic Oncology
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- (2016) Fabrice Barlesi et al. LANCET
- Equal access to innovative therapies and precision cancer care
- (2016) Agnès Buzyn et al. Nature Reviews Clinical Oncology
- MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
- (2016) Difan Zheng et al. Oncotarget
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
- (2012) Hiroyuki Yasuda et al. Journal of Thoracic Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More